Research location
North Canton
Ohio, United States
Advertisement
Research activity in North Canton
Ohio, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 71 trials and 72 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in North Canton
71 linked trials · page 1 of 2A Long-Term Open-Label Study of ML-007C-MA in Adults With SchizophreniaNCT07459647 · 2026-03-31 · 1 site observation
RECRUITING
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute SchizophreniaNCT07363577 · 2026-03-25 · 1 site observation
RECRUITING
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT07222566 · 2026-01-06 · 1 site observation
RECRUITING
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant ResponseNCT07284667 · 2025-11-14 · 1 site observation
RECRUITING
A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With SchizophreniaNCT07191483 · 2025-08-27 · 1 site observation
RECRUITING
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With SchizophreniaNCT07105098 · 2025-08-11 · 1 site observation
RECRUITING
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)NCT07033494 · 2025-07-16 · 1 site observation
RECRUITING
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With SchizophreniaNCT07114874 · 2025-07-11 · 1 site observation
RECRUITING
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)NCT07065240 · 2025-06-19 · 1 site observation
RECRUITING
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)NCT06524830 · 2024-12-30 · 1 site observation
RECRUITING
A Randomized Study of Azetukalner Versus Placebo in Major Depressive DisorderNCT06775379 · 2024-12-20 · 1 site observation
RECRUITING
ALTO-100 in Bipolar Disorder With Depression (BD-D)NCT06656416 · 2024-10-02 · 1 site observation
RECRUITING
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD DementiaNCT06584357 · 2024-09-26 · 1 site observation
RECRUITING
An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)NCT07161700 · 2025-09-02 · 1 site observation
ENROLLING_BY_INVITATION
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With SchizophreniaNCT07038876 · 2025-06-27 · 1 site observation
COMPLETED
RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or OverweightNCT06987513 · 2025-05-15 · 1 site observation
COMPLETED
A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's DiseaseNCT06881836 · 2025-04-24 · 1 site observation
ACTIVE_NOT_RECRUITING
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With SchizophreniaNCT06894212 · 2025-02-28 · 1 site observation
ACTIVE_NOT_RECRUITING
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"NCT06564818 · 2024-12-17 · 1 site observation
ACTIVE_NOT_RECRUITING
PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)NCT06750432 · 2024-12-13 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive MedicineNCT06280235 · 2024-03-27 · 1 site observation
COMPLETED
A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive DisorderNCT06267846 · 2024-03-20 · 1 site observation
COMPLETED
A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive DisorderNCT06340958 · 2024-03-18 · 1 site observation
COMPLETED
Study Evaluating Safety and Efficacy of Ropanicant in MDD PatientsNCT06126497 · 2024-02-05 · 1 site observation
COMPLETED
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive DisorderNCT06058013 · 2023-12-20 · 1 site observation
COMPLETED
Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute SchizophreniaNCT06179108 · 2023-11-29 · 1 site observation
COMPLETED
Study to Assess the Safety and Effectiveness of NMRA-335140-501NCT06029439 · 2023-11-10 · 1 site observation
TERMINATED
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's DiseaseNCT06079190 · 2023-10-20 · 1 site observation
TERMINATED
A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With SchizophreniaNCT05848700 · 2023-06-21 · 1 site observation
COMPLETED
A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With SchizophreniaNCT05693935 · 2023-01-24 · 1 site observation
COMPLETED
A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's DiseaseNCT05644977 · 2022-12-02 · 1 site observation
COMPLETED
Open-label Extension for Phase 3 Clinical Trials of SimufilamNCT05575076 · 2022-11-07 · 1 site observation
TERMINATED
Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With SchizophreniaNCT05545111 · 2022-10-04 · 1 site observation
COMPLETED
A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)NCT05466422 · 2022-09-20 · 1 site observation
COMPLETED
Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive DisorderNCT05536414 · 2022-09-12 · 1 site observation
COMPLETED
A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With SchizophreniaNCT05443724 · 2022-09-01 · 1 site observation
TERMINATED
A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With SchizophreniaNCT05463770 · 2022-08-30 · 1 site observation
COMPLETED
A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With SchizophreniaNCT05227690 · 2022-06-30 · 1 site observation
COMPLETED
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's DiseaseNCT05310071 · 2022-06-02 · 1 site observation
TERMINATED
A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).NCT05227209 · 2022-03-17 · 1 site observation
TERMINATED
Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)NCT05203341 · 2022-02-21 · 1 site observation
COMPLETED
Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With SchizophreniaNCT05245539 · 2022-01-24 · 1 site observation
COMPLETED
A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.NCT05169710 · 2021-12-21 · 1 site observation
TERMINATED
Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's DiseaseNCT05026177 · 2021-11-18 · 1 site observation
TERMINATED
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)NCT04846868 · 2021-09-08 · 1 site observation
COMPLETED
A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive MedicationNCT04937829 · 2021-07-20 · 1 site observation
COMPLETED
Lumateperone for the Prevention of Relapse in Patients With SchizophreniaNCT04959032 · 2021-07-08 · 1 site observation
COMPLETED
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)NCT04820309 · 2021-06-02 · 2 site observations
COMPLETED
An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)NCT04659174 · 2021-02-01 · 1 site observation
COMPLETED
A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of SuicideNCT04669665 · 2020-12-17 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.